Supernus Pharmaceuticals【0LB2】銘柄情報

Supernus Pharmaceuticals Inc (0LB2) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

55.00

( - )

買値

55.00

売値

55.00

出来高

0.00 日の範囲 0.00

55.00 52 週間の範囲 55.00

時価総額

3.192B

前日終値

55.00

始値

時刻

45.05

(O)

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

US$ 647,838

発行済株式数

58,039,721

配当利回り

PER

-86.35

1 株当たり利益 (EPS)

-0.51

歳入

776.83M

純利益

-29.02M

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity... Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland. 詳細を表示

セクター

業界

ウェブサイト

www.supernus.com

本社

Rockville, United States

設立

2026

Supernus Pharmaceuticals Inc is listed in the sector of the ロンドン証券取引所 with ticker 0LB2. The last closing price for Supernus Pharmaceuticals was US$55. Over the last year, Supernus Pharmaceuticals shares have traded in a share price range of US$ 55.00 to US$ 55.00.

Supernus Pharmaceuticals currently has 58,039,721 shares in issue. The market capitalisation of Supernus Pharmaceuticals is US$3.19 billion. Supernus Pharmaceuticals has a price to earnings ratio (PE ratio) of -86.35.

表示するニュースはありません。